



Individuals with Scientific or Medical Training - Survey Feedback

Purpose: This document presents feedback submitted through the 2026 survey for individuals with scientific or medical training. The table reproduces the substantive survey information provided by respondents. Note: Survey responses reflect the experience and opinions of individual respondents and have not been independently verified by PDAB. Blank survey items are shown as “No response.”

Xolair (omalizumab)

Primary professional role	Pharmacist or pharmacy professional
Years of experience treating or studying this condition	More than 10 years
Practice setting	Specialty Pharmacy
Typical role of this drug treatment	Second-line therapy
Patient population most commonly receiving this drug	Narrow / highly specific
Is this drug clinically substitutable for at least one alternative?	Yes, for some patients
Compared to therapeutic alternatives, this drug provides	Similar benefit
Strength of evidence supporting use for its primary indication	High (multiple RCTs, guideline-supported)
Off-label use in your practice or system	Occasional
Utilization management requirement typically associated with this drug (Select all that apply)	Prior authorization; Step therapy; Quantity limits; Specialty pharmacy requirement;
Administrative burden relative to alternatives	Somewhat higher
Does utilization management delay patient access	Frequently
In your experience, patient out-of-pocket costs for this drug are	Similar



Have patients delayed or declined treatment due to cost?	Occasionally
Impact of patient cost on adherence	Moderate impact
Are there other impacts that cause adherence issues?	Beyond cost, adherence to Xolair is affected by administration burden (frequent dosing, clinic visits, anaphylaxis monitoring), psychological factors (injection fear, illness denial, depression), clinical factors (perceived benefit, symptom control), and systemic barriers (insurance complexity, specialist access). Self-administration options may improve adherence for appropriate patients.
Availability of the drug when clinically needed	Occasionally delayed
If delays occur, primary cause	Payer authorization
Overall impact of this drug on health system costs	Increases costs moderately
Overall value of this drug relative to its cost	Moderate value
From a clinical perspective, does this drug contribute to affordability concerns for patients?	Yes
Is there anything else you would like PDAB to know about this medication?	No.
If you could change one thing about how this prescription drug is priced or accessed in Oregon, what would it be?	The most helpful change Oregon could make would be to simplify prior authorization by using clear standard criteria and faster approval timelines. This would reduce treatment delays and improve access, while other policies like out-of-pocket caps and support for biosimilars could further improve affordability.